A. Hunter

发表

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

M. Dyer, S. O’Rahilly, N. Wareham, 2009, The Journal of clinical investigation.

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

Lars Kjeldsen, Robert K Hills, Keith Wheatley, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

R. Hills, N. Russell, M. Dennis, 2014 .

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

A. Rohatiner, R. Clark, A. Hunter, 2003 .

High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

N. Schmitz, A. Hunter, C. Kyriakou, 2008 .

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial

R. Hills, N. Russell, A. Hunter, 2013, Leukemia.

Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial

C. Crawley, A. Hunter, G. Cook, 2009, Bone Marrow Transplantation.

T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.

S. Mackinnon, K. Peggs, A. Hunter, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

lymphoma transplantation regimen for relapsed and refractory non-Hodgkin Outcomes after alemtuzumab-containing reduced-intensity allogeneic

C. Craddock, S. Mackinnon, K. Peggs, 2008 .

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, L. Kanz, N. Russell, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes

J. Garcia-conde, J. Sierra, S. Mackinnon, 2007, British journal of haematology.

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

C. Craddock, S. Mackinnon, K. Peggs, 2005, The Lancet.

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma

N. Russell, K. Peggs, A. Hunter, 2018, British journal of haematology.

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia positive cells including primary CML stem cells

Paolo, Salomoni, M. Dyer, 2009 .

transplantation lymphoma patients undergoing autologous peripheral blood stem cell

N. Schmitz, A. Hunter, G. Guillerm, 2011 .

Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.

N. Schmitz, A. Hunter, P. Biron, 2009, Blood.

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

C. Craddock, R. Hills, N. Russell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

R. Hills, N. Russell, L. Kjeldsen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, A. Hunter, C. Kyriakou, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantati

H. Einsele, G. Mufti, A. Hunter, 2006, Blood.

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

R. Hills, N. Russell, A. Hunter, 2013, Leukemia.

The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome

R. Hills, N. Russell, A. Hunter, 2011, Leukemia.

Differential toxicity of α‐keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro

A. Hunter, A. Hoffbrand, L. Sheppard, 1994, European journal of haematology.

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.

R. Hills, N. Russell, A. Hunter, 2013, Blood.

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.

R. Hills, N. Russell, A. Hunter, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

R. Hills, N. Russell, M. Dennis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.

R. Hills, N. Russell, L. Kjeldsen, 2009 .

Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia.

C. Craddock, S. Mackinnon, K. Peggs, 2001 .

Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission.

A. Hunter, H. Prentice, A. Hoffbrand, 1991, Bone marrow transplantation.

Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.

A. Hunter, N. Russell, A. Haynes, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.

A. Hunter, H. Prentice, J. Upward, 1991, Bone marrow transplantation.

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

R. Hills, N. Russell, L. Kjeldsen, 2011 .

Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation

N. Russell, A. Hunter, J. Hanley, 1993, The Lancet.

Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)

N. Schmitz, T. Haferlach, N. Russell, 1995, Blood.

Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia.

N. Russell, A. Hunter, F. Keith, 1995, Leukemia & lymphoma.

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

R. Hills, N. Russell, A. Hunter, 2010 .

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

J. Garcia-conde, C. Craddock, S. Mackinnon, 2002, Blood.

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

S. Mackinnon, K. Peggs, A. Hunter, 2008, Bone Marrow Transplantation.

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

C. Craddock, S. Mackinnon, K. Peggs, 2002, Blood.

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

R. Hills, N. Russell, A. Hunter, 2007 .

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

P. Vyas, C. Craddock, S. Siddique, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone marrow transplantation: current situation, complications and prevention.

A. Hunter, N. Russell, A. Haynes, 1995, The Journal of antimicrobial chemotherapy.

Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia.

N. Russell, A. Hunter, N. Russell, 1993, Blood.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

N. Kröger, S. Iacobelli, C. Crawley, 2018, Haematologica.

Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an ∼700 kDa Apaf-1 containing apoptosome complex

A. Hunter, D. Dinsdale, K. Cain, 2001, Leukemia.

Peripheral blood stem cells for allogeneic transplantation.

N. Russell, A. Hunter, 1994, Bone Marrow Transplantation.

Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF.

A. Hunter, N. Russell, A. Haynes, 1995, Bone marrow transplantation.

Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A.

N. Russell, A. Hunter, E. Bessell, 1992, Bone marrow transplantation.

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

C. Craddock, N. Russell, S. Mackinnon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.

C. Craddock, S. Mackinnon, K. Peggs, 2004, Blood.

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

R. Hills, N. Russell, L. Kjeldsen, 2013 .

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

R. Hills, N. Russell, R. Clark, 2015, The Lancet. Oncology.

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial

R. Hills, J. Takita, A. Hunter, 2018, Leukemia.

The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma

S. Montoto, J. Delgado, A. Hunter, 2011, Leukemia.

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

R. Hills, N. Russell, R. Clark, 2013 .

The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial.

R. Hills, N. Russell, A. Hunter, 2006 .

Risk factors for acute graft-versus-host disease associated with cyclosporine and methotrexate prophylaxis [letter; comment]

N. Russell, A. Hunter, S. Rogers, 1993 .

Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).

C. Craddock, S. Mackinnon, K. Peggs, 2002 .

Extramedullary haemopoiesis as a cause of mediastinal lymphadenopathy in chronic myelomonocytic leukaemia.

A. Hunter, N. Russell, I. Ellis, 2008, Clinical and laboratory haematology.

Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex.

G. Cohen, A. Hunter, D. Dinsdale, 2001, Leukemia.

Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect.

C. Craddock, S. Mackinnon, A. Hunter, 2001 .

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

R. Hills, N. Russell, R. Clark, 2013 .

Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)

C. Craddock, S. Mackinnon, K. Peggs, 2004 .

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

A. Rohatiner, R. Clark, A. Hunter, 2003, Blood.

Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: Evidence of a therapeutically relevant graft-versus-lymphoma effect.

C. Craddock, S. Mackinnon, A. Hunter, 2003 .